TTY Biopharm Company Limited (TPEX:4105)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
73.10
+1.00 (1.39%)
Apr 28, 2026, 1:30 PM CST
-1.62%
Market Cap 18.18B
Revenue (ttm) 6.45B
Net Income (ttm) 1.56B
Shares Out 248.65M
EPS (ttm) 6.26
PE Ratio 11.68
Forward PE 10.69
Dividend 4.50 (6.24%)
Ex-Dividend Date Mar 26, 2026
Volume 507,723
Average Volume 853,944
Open 73.20
Previous Close 72.10
Day's Range 72.60 - 73.40
52-Week Range 71.60 - 87.00
Beta 0.17
RSI 35.82
Earnings Date Mar 27, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin,... [Read more]

Sector Healthcare
Founded 1960
Employees 342
Stock Exchange Taipei Exchange
Ticker Symbol 4105
Full Company Profile

Financial Performance

In 2025, TTY Biopharm Company's revenue was 6.45 billion, an increase of 9.49% compared to the previous year's 5.89 billion. Earnings were 1.56 billion, an increase of 7.55%.

Financial Statements

News

There is no news available yet.